

FY1920 Q3 Performance in Delivering

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Total Number Of Study Participants Recruited	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial
17/YH/0329	216857	A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease	Number Agreed	6	6	Date Agreed	04/02/2019	0	0	05/04/2019	Withdrawn By Sponsor
18/LO/0731	246135	The Effects of Psilocybin on Cognitive Function in Healthy Participants	Number Agreed	90	90	Date Agreed	25/04/2019	90	90	30/04/2019	Recruitment Finished
18/SC/0433	249835	A Phase I, randomized, placebo-controlled, open-label, three period crossover study to investigate the effect of darolutamide and enzalutamide on cerebral blood flow in healthy male volunteers.	Number Agreed	24	24	Date Agreed	18/01/2019	26	26	09/04/2019	Recruitment Finished

FY1920 Q3 Performance in Delivering

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Total Number Of Study Participants Recruited	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial
17/YH/0195	228739	A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Second Generation Antipsychotics in Subjects With Stable Schizophrenia	Number Agreed	15	15	Date Agreed	30/09/2019	20	20	02/08/2019	Recruitment Finished
15/SS/0032	165287	An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease	Number Agreed	6	6	Date Agreed	28/02/2019	7	7	28/02/2019	Recruitment Finished

FY1920 Q3 Performance in Delivering

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Total Number Of Study Participants Recruited	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial
18/LO/0128	240068	A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System with Healthcare Professionals and Adult Subjects with Schizophrenia, Schizoaffective Disorder, or First Episode Ps	Range Agreed	5	15	Date Agreed	13/02/2019	14	14	03/05/2019	Recruitment Finished
18/EE/0151	244573	A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies (DELPHIA)	Number Agreed	5	5	Date Agreed	20/11/2019	2	2	15/11/2019	Recruitment Finished

FY1920 Q3 Performance in Delivering

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Total Number Of Study Participants Recruited	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial
18/WS/0040	204214	A phase II randomised, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patients with Schizophrenia.	Number Agreed	5	5	Date Agreed	31/07/2019	6	6	18/11/2019	Recruitment Finished